Navigation Links
EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124
Date:5/11/2010

.

Two previous studies with EVP-6124 in Alzheimer's disease patients demonstrated that it was well tolerated and produced significant effects on a variety of cognitive measures of brain function such as attention, memory and executive function (complex thinking tasks). EVP-6124 had procognitive effects in two separate clinical trials: one study conducted in Alzheimer's disease patients already treated with Acetyl Choline Esterase Inhibitors (AChEI) and one in Alzheimer's disease patients not on AChEI therapy (naive patients).

EVP-6124 is a selective agonist for the alpha-7 subtype of the nicotinic acetylcholine receptor and is being developed by EnVivo for potential cognitive enhancement in both schizophrenia and Alzheimer's patients. It has been shown to have excellent CNS penetration, oral bioavailability, pharmacokinetics and metabolic profile.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, cognitive disorders and schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase IIa clinical trials for cognition disorders in Alzheimer's disease and schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which has completed Phase I studies, and seve
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
3. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
4. EnVivo Pharmaceuticals Announces Executive Appointment
5. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
6. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
7. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
10. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
11. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Port Washington, NY (PRWEB) May 22, 2013 ... most comprehensive line of accessories for the mobile lifestyle, ... to charge, sync, protect, and manage multiple iPad devices ... design award and the 2012 Good Design award, MultiCharger-X ... utilize the iPad, wherever it is deployed. , ...
(Date:5/22/2013)... New York (PRWEB) May 22, 2013 ... the 3rd Annual Disruptive Innovations to Advance Clinical Trials ... Copley Plaza Hotel in Boston, MA. , Disruptive ... Janssen Pharmaceuticals and more share bold approaches to reduce ... , “Disruptive innovation needs to be big, or ...
(Date:5/22/2013)... BUFFALO, N.Y. , May 22, 2013 /PRNewswire/ ... exclusive license for a patent pending novel genomic ... a molecular diagnostic test that could help in ... (NEPC) prostate cancer.  Neuroendocrine prostate ... adenocarcinoma (PCA) that can arise de novo, but ...
(Date:5/22/2013)... NEW ORLEANS , May 22, 2013  Organogenesis ... medicine, presented new data generated in collaboration with a ... health economics consultancy) demonstrating the significant healthcare resource and ... leg ulcers (VLU) place upon the US healthcare system. ... reveal annual costs of up to $15 billion and ...
Breaking Biology Technology:iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4
... 25 Encision Inc. ("Encision") (OTC Bulletin Board: ECIA), ... is emerging as a standard of care in minimally-invasive ... Inc. ("Caldera") to represent Caldera,s line of products. ... stress urinary incontinence which is estimated to affect 15 ...
... Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ... in its U.K. clinical trial to evaluate the ... combination with gemcitabine (Gemzar(R)) in patients with advanced ... principal investigators are Dr. Johann de Bono of ...
... is a true super hero to Senator Katherine Laforge. With stakes higher ... energy crisis that threatens to enslave America to OPEC forever. The message ... that alternative energy can free us from OPEC and put an end to ... ...
Cached Biology Technology:Encision Enters Into Sales Representation Agreement With Caldera Medical 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3Batman Teams with Senator Katherine Laforge to Help Free America from OPEC 2Batman Teams with Senator Katherine Laforge to Help Free America from OPEC 3Batman Teams with Senator Katherine Laforge to Help Free America from OPEC 4Batman Teams with Senator Katherine Laforge to Help Free America from OPEC 5
(Date:5/22/2013)... (NLST) investigators also conclude that the 20 percent ... tomography (LDCT) versus chest X-ray (CXR) screening previously ... at experienced screening centers in the United States. ... with their patients about the benefits and risks ... in the New England Journal of Medicine ...
(Date:5/22/2013)... Harvard physicists have developed a novel technique that can ... a process that is one of the most important, ... described in a paper in Nature , post-doctoral ... Dr. Melanie Schnell of the Center for Free-Electron Laser ... relies on finely-tuned microwave fields to identify molecular variants ...
(Date:5/22/2013)... Md. (May 22, 2013)The omega 3 fatty acids in ... cardiovascular diseaseso much so that the American Heart Association ... a week, particularly fatty varieties rich in omega 3s. ... a mystery. In a new study, scientists led by ... on this phenomenon by providing evidence that fish oil ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3Detecting mirror molecules 2Detecting mirror molecules 3Fish oil may help the heart beat mental stress 2
... Electronic products pollute our environment with a number of ... the U.S. alone, an estimated 70% of heavy metals ... TVs getting bigger and cheaper every year, environmental costs ... new Tel Aviv University solution applies a discovery in ...
... scientists claim that a new method of testing ... rapid and non-invasively method of diagnosing degenerative disorders. ... Comparative Neurology , reveals that Magnetic Resonance Spectroscopy ... allowing earlier diagnosis. The diagnosis of ...
... the Entomological Society of America, will feature two plenary ... 12-15, 2010. Christopher Marley, an author and insect ... "insect-phobe" into an aficionado during a speech called "The ... CA in the late 1960,s, where he had a ...
Cached Biology News:'Greening' your flat screen TV 2Research heralds potential for early diagnosis of degenerative brain disorders 2Christopher Marley and James McWilliams to give plenary speeches at Entomology 2010 2
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... acid hybridization Preparation Reconstitution: one ... 50 mg ficoll and 50 ... ml of water yields a ... biology Density: 1.00 g/mL (20 ...
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
...
Biology Products: